Clinical trial · Interventional
18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
Prospective Study of 18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
NCT05983796CI-TRIAL-00068687unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a open-label, one-arm, multicenter study aimed to explore the efficacy and safety of 18F-HER2 PET in Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| 18F-HER2 PET | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 18F-HER2 PET | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- 18F-HER2 PET
- interventionNames
- Diagnostic Test: 18F-HER2 PET
Primary outcomes (1)
- measure
- Evaluating the Efficacy of Anti-HER2 Therapy for Urothelial Carcinoma
- timeFrame
- up to 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: 1. Informed consent document must be signed. 2. Aged 30-80 years old, both genders. 3. Patients with locally advanced or advanced urothelial carcinoma 4. Patients plan to undergo anti HER2 treatment. Exclusion Criteria: 1. Subjects with active malignancies other than urothelial carcinoma within 5 years should be excluded. 2. Patients with severe liver, kidney, and hematopoietic diseases 3. Patients with other mental disorders or primary emotional disorders 4. Those who are unable to understand, comply with the research protocol, or sign an informed consent form 5. PET imaging Contraindication (including pregnant women, lactating women, women of childbearing age who have a recent fertility plan, etc.) 6. Individuals who are allergic to imaging agents 7. Hypoglycemic reactions, severe pain, etc. cannot be accompanied by PET scans
References
Publications (0)
Data not yet available
No reference posted for this study.